Ligand Pharmaceuticals Inc.  

(Public, NASDAQ:LGND)   Watch this stock  
Find more results for LGND
85.79
-2.47 (-2.80%)
After Hours: 85.79 0.00 (0.00%)
Feb 11, 4:35PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 82.06 - 90.47
52 week 54.62 - 114.00
Open 89.77
Vol / Avg. 656,611.00/465,870.00
Mkt cap 1.68B
P/E 7.18
Div/yield     -
EPS 11.95
Shares 19.92M
Beta 1.03
Inst. own 126%
May 9, 2016
Q1 2016 Ligand Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 10, 2016
Q4 2015 Ligand Pharmaceuticals Inc Earnings Call
Feb 10, 2016
Q4 2015 Ligand Pharmaceuticals Inc Earnings Release
Dec 17, 2015
Ligand Pharmaceuticals Inc Conference Call to Discuss Acquistion of OMT Inc
Nov 18, 2015
Ligand Pharmaceuticals Inc Analyst Day
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 1268.51% 16.88%
Operating margin 48.57% 30.41%
EBITD margin - 36.27%
Return on average assets 217.95% 6.01%
Return on average equity 498.64% 31.67%
Employees 19 -
CDP Score - -

Address

11119 N Torrey Pines Rd Ste 200
LA JOLLA, CA 92037-1028
United States - Map
+1-858-5507500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Company's technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases, such as hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis (FSGS) and osteoporosis.

Officers and directors

John W. Kozarich Ph.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Matthew W. Foehr President, Chief Operating Officer
Age: 42
Bio & Compensation  - Reuters
John L. Higgins Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Matthew E Korenberg Chief Financial Officer, Vice President - Finance
Bio & Compensation  - Reuters
Charles S. Berkman J.D. Vice President, General Counsel, Secretary
Age: 46
Bio & Compensation  - Reuters
Jason M. Aryeh Independent Director
Age: 46
Bio & Compensation  - Reuters
Todd C. Davis Independent Director
Age: 54
Bio & Compensation  - Reuters
David M. Knott Independent Director
Age: 70
Bio & Compensation  - Reuters
John L. LaMattina Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Sunil Patel Independent Director
Age: 43
Bio & Compensation  - Reuters